156 related articles for article (PubMed ID: 37782758)
1. Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
Garbowski MW; Ugidos M; Risueño A; Shetty JK; Schwickart M; Hermine O; Porter JB; Thakurta A; Vodala S
Am J Hematol; 2024 Feb; 99(2):182-192. PubMed ID: 37782758
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
[TBL] [Abstract][Full Text] [Related]
3. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
[TBL] [Abstract][Full Text] [Related]
4. The use of luspatercept for thalassemia in adults.
Cappellini MD; Taher AT
Blood Adv; 2021 Jan; 5(1):326-333. PubMed ID: 33570654
[TBL] [Abstract][Full Text] [Related]
5. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
[No Abstract] [Full Text] [Related]
6. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
7. The effect of erythroferrone suppression by transfusion on the erythropoietin-erythroferrone-hepcidin axis in transfusion-dependent thalassaemia: A pre-post cohort study.
Zaman BA; Rasool SO; Abdo JM
Br J Haematol; 2023 May; 201(3):547-551. PubMed ID: 36535905
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
Tanzi E; Di Modica SM; Bordini J; Olivari V; Pagani A; Furiosi V; Silvestri L; Campanella A; Nai A
Am J Hematol; 2024 Jul; 99(7):1313-1325. PubMed ID: 38629683
[TBL] [Abstract][Full Text] [Related]
9. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
[TBL] [Abstract][Full Text] [Related]
12. Luspatercept for β-thalassemia: beyond red blood cell transfusions.
Taher AT; Cappellini MD
Expert Opin Biol Ther; 2021 Nov; 21(11):1363-1371. PubMed ID: 34404288
[TBL] [Abstract][Full Text] [Related]
13. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
[TBL] [Abstract][Full Text] [Related]
14. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
[TBL] [Abstract][Full Text] [Related]
15. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Langdon JM; Barkataki S; Berger AE; Cheadle C; Xue QL; Sung V; Roy CN
Am J Hematol; 2015 Jan; 90(1):8-14. PubMed ID: 25236856
[TBL] [Abstract][Full Text] [Related]
16. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
17. Development of luspatercept to treat ineffective erythropoiesis.
Kubasch AS; Fenaux P; Platzbecker U
Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
[TBL] [Abstract][Full Text] [Related]
18. Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.
Martinez PA; Li R; Ramanathan HN; Bhasin M; Pearsall RS; Kumar R; Suragani RNVS
J Cell Mol Med; 2020 Jun; 24(11):6162-6177. PubMed ID: 32351032
[TBL] [Abstract][Full Text] [Related]
19. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
20. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.
Li H; Choesang T; Bao W; Chen H; Feola M; Garcia-Santos D; Li J; Sun S; Follenzi A; Pham P; Liu J; Zhang J; Ponka P; An X; Mohandas N; Fleming RE; Rivella S; Li G; Ginzburg YZ
Blood; 2017 Mar; 129(11):1514-1526. PubMed ID: 28151426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
